(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2.50% ¥ 410.00
Live Chart Being Loaded With Signals
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally...
Stats | |
---|---|
Объем за сегодня | 1.42M |
Средний объем | 3.35M |
Рыночная капитализация | 162.89B |
EPS | ¥0 ( 2024-01-31 ) |
Дата следующего отчета о доходах | ( ¥-323.99 ) 2024-05-13 |
Last Dividend | ¥7.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -0.940 |
ATR14 | ¥0.448 (0.11%) |
Объем Корреляция
Sumitomo Pharma Co., Ltd. Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Sumitomo Pharma Co., Ltd. Корреляция - Валюта/Сырье
Sumitomo Pharma Co., Ltd. Финансовые показатели
Annual | 2022 |
Выручка: | ¥555.54B |
Валовая прибыль: | ¥376.63B (67.79 %) |
EPS: | ¥-187.55 |
FY | 2022 |
Выручка: | ¥555.54B |
Валовая прибыль: | ¥376.63B (67.79 %) |
EPS: | ¥-187.55 |
FY | 2022 |
Выручка: | ¥560.04B |
Валовая прибыль: | ¥402.91B (71.94 %) |
EPS: | ¥102.19 |
FY | 2021 |
Выручка: | ¥515.95B |
Валовая прибыль: | ¥378.18B (73.30 %) |
EPS: | ¥141.50 |
Financial Reports:
No articles found.
Sumitomo Pharma Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥14.00 (N/A) |
¥0 (N/A) |
¥7.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.75 | 2000-03-28 |
Last Dividend | ¥7.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 47 | -- |
Total Paid Out | ¥382.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.47 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8142.T | Ex Dividend Knight | 2024-01-30 | Annually | 0 | 0.00% | |
7506.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6727.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
6071.T | Ex Dividend Knight | 2023-12-28 | Annually | 0 | 0.00% | |
4746.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3988.T | Ex Dividend Junior | 2024-07-30 | Annually | 0 | 0.00% | |
3197.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2201.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
9065.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7949.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.526 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.164 | 1.200 | -5.46 | -6.56 | [0 - 0.3] |
returnOnEquityTTM | -0.440 | 1.500 | -6.00 | -9.00 | [0.1 - 1] |
payoutRatioTTM | -0.0161 | -1.000 | -0.161 | 0.161 | [0 - 1] |
currentRatioTTM | 0.627 | 0.800 | -1.864 | -1.491 | [1 - 3] |
quickRatioTTM | 0.333 | 0.800 | -2.75 | -2.20 | [0.8 - 2.5] |
cashRatioTTM | 0.0866 | 1.500 | -0.630 | -0.945 | [0.2 - 2] |
debtRatioTTM | 0.389 | -1.500 | 3.52 | -5.29 | [0 - 0.6] |
interestCoverageTTM | -8.87 | 1.000 | -4.40 | -4.40 | [3 - 30] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 1.199 | -1.500 | 5.20 | -7.81 | [0 - 2.5] |
grossProfitMarginTTM | 0.599 | 1.000 | 3.34 | 3.34 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.536 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.669 | 1.000 | -4.83 | -4.83 | [0.2 - 2] |
assetTurnoverTTM | 0.312 | 0.800 | -1.256 | -1.005 | [0.5 - 2] |
Total Score | -5.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.938 | 1.000 | -0.196 | 0 | [1 - 100] |
returnOnEquityTTM | -0.440 | 2.50 | -3.86 | -9.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.0161 | 1.500 | -0.161 | 0.161 | [0 - 1] |
pegRatioTTM | -2.71 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.834 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -5.01 |
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа